In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling

Cardiovascular Research

Volumn 93, Issue 3, 2012, Pages 463-470

  Becker, Jason R ^a   Robinson, Tamara Y ^a   Sachidanandan, Chetana ^b   Kelly, Amy E ^c   Coy, Shannon ^c   Peterson, Randall T ^b   MacRae, Calum A ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Heart development; Heart failure; Hypertrophic cardiomyopathy; Hypertrophy; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL ANALYSIS; EMBRYO; GENE CONTROL; GENE EXPRESSION; GENETIC SCREENING; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BUTADIENES; CARDIOMYOPATHY, HYPERTROPHIC; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENES, REPORTER; GENETIC MARKERS; GENETIC TESTING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUCIFERASES; MAMMALS; NATRIURETIC PEPTIDES; NITRILES; SIGNAL TRANSDUCTION; ZEBRAFISH;

EID: 84857519732     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr350     Document Type: Article

References (22)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-486.
2. Schlueter PJ, Peterson RT. Systematizing serendipity for cardiovascular drug discovery. Circulation 2009;120:255-263.
3. Knowlton KU, Rockman HA, Itani M, Vovan A, Seidman CE, Chien KR. Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. J Clin Invest 1995;96:1311-1318.
4. Horsthuis T, Houweling AC, Habets PE, de Lange FJ, El Azzouzi H, Clout de et al. Distinct regulation of developmental and heart disease-induced atrial natriuretic factor expression by two separate distal sequences. Circ Res 2008;102:849-859.
5. Auman HJ, Coleman H, Riley HE, Olale F, Tsai HJ, Yelon D. Functional modulation of cardiac form through regionally confined cell shape changes. PLoS Biol 2007;5:e53.
6. Becker JR, Deo RC, Werdich AA, Panakova D, Coy S, MacRae CA. Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish. Dis Model Mech 2011;4:400-410.
7. Sehnert AJ, Huq A, Weinstein BM, Walker C, Fishman M, Stainier DY. Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. Nat Genet 2002;31:106-110.
8. Zhong TP, Rosenberg M, Mohideen MA, Weinstein B, Fishman MC. Gridlock, an HLH gene required for assembly of the aorta in zebrafish. Science 2000;287:1820-1824.
9. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson en et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006;113:2579-2588.
10. Small EM, Krieg PA. Transgenic analysis of the atrialnatriuretic factor (ANF) promoter: Nkx2-5 and GATA-4 binding sites are required for atrial specific expression of ANF. Dev Biol 2003;261:116-131.
11. La Pointe MC. Molecular regulation of the brain natriuretic peptide gene. Peptides 2005;26:944-956.
12. Shin JT, Priest JR, Ovcharenko I, Ronco A, Moore RK, Burns CG et al. Humanzebrafish non-coding conserved elements act in vivo to regulate transcription. Nucleic Acids Res 2005;33:5437-5445.
13. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998;95:2979-2984.
14. Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp Cell Res 1976;98:367-381.
15. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47-72.
16. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Di Bianco R, Zeldis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475.
17. Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986;112:787-791.
18. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
19. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC et al. Extracellular signalregulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 2000;275:37895-37901.
20. Lorenz K, Schmitt JP, Vidal M, Lohse MJ. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol 2009;41:2351-2355.
21. Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1 (L613V) mutation. J Clin Invest 2011;121:1009-1025.
22. Ashrafian H, McKenna WJ, Watkins H. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res 2011;109:86-96.